Statement of Commissioners Chopra and Slaughter Regarding the Federal Trade Commission Report on the Use of Section 5 to Address Off-Patent Pharmaceutical Price Spikes

Share This Page

• Facebook
• Twitter
• Linked-In

Tags:

• Manufacturing
• Pharmaceuticals
• Competition
• Section 5

Regarding the Federal Trade Commission Report on the Use of Section 5 to Address Off-Patent Pharmaceutical Price Spikes

Date: June 27, 2019

By: 

Rohit Chopra, Commissioner;

Rebecca Kelly Slaughter, Commissioner

Statement of Commissioners Chopra and Slaughter Regarding the Federal Trade Commission Report on the Use of Section 5 to Address Off-Patent Pharmaceutical Price Spikes (68.34 KB)

FTC Report on Standalone Section 5 to Address High Pharmaceutical Drug and Biologic Prices